We also detected two ESR1 mutations, both with a 3A LoE (Fig. 5B) and three somatic variants in familial BC genes, reported to respond to PARP inhibitors (two BRCA2 and one PALB1 variants) (Additional file 10: Table S8). This evidence concerns the gene ESR1 and breast cancer.